152 related articles for article (PubMed ID: 7709763)
1. The effect of intranasal salmon calcitonin on biochemical parameters of bone turnover in postmenopausal women.
Balint-Perić LA; Prelević GM; Beslagić Z; Petrović J
Gynecol Endocrinol; 1994 Dec; 8(4):241-5. PubMed ID: 7709763
[TBL] [Abstract][Full Text] [Related]
2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
[TBL] [Abstract][Full Text] [Related]
4. Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study.
Grigoriou O; Papoulias I; Vitoratos N; Papadias C; Konidaris S; Antoniou G; Chryssikopoulos A
Maturitas; 1997 Dec; 28(2):147-51. PubMed ID: 9522322
[TBL] [Abstract][Full Text] [Related]
5. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment.
Kraenzlin ME; Seibel MJ; Trechsel U; Boerlin V; Azria M; Kraenzlin CA; Haas HG
Calcif Tissue Int; 1996 Apr; 58(4):216-20. PubMed ID: 8661950
[TBL] [Abstract][Full Text] [Related]
6. Effects of cyclic therapy with intranasal carbocalcitonin in healthy spontaneous postmenopausal women.
De Aloysio D; Pansini F; Campobasso C; Zanotti L; Abbruzzese AD; Mauloni M; Bottiglioni F
Clin Exp Obstet Gynecol; 1996; 23(2):87-93. PubMed ID: 8737620
[TBL] [Abstract][Full Text] [Related]
7. [Calcium-phosphorus metabolism and bone metabolism in postmenopausal patients with the thyroid gland pathology].
Esedova AE; Gadzhieva MM; Ferzilaeva RA
Klin Lab Diagn; 2002 Mar; (3):13-6. PubMed ID: 11980136
[TBL] [Abstract][Full Text] [Related]
8. Acute effects of nasal salmon calcitonin on calcium and bone metabolism.
Thamsborg G; Skousgaard SG; Daugaard H; Schifter S; Kollerup G; Sørensen OH
Calcif Tissue Int; 1993 Oct; 53(4):232-6. PubMed ID: 8275350
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
[TBL] [Abstract][Full Text] [Related]
10. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
[TBL] [Abstract][Full Text] [Related]
11. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.
Mango D; Ricci S; Manna P; Natili G; Dell'Acqua S
Minerva Endocrinol; 1993 Sep; 18(3):115-21. PubMed ID: 8183178
[TBL] [Abstract][Full Text] [Related]
12. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
13. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
Overgaard K; Hansen MA; Nielsen VA; Riis BJ; Christiansen C
Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of mineral metabolism and bone turnover in osteoporotic females treated with phosphorus and salmon calcitonin.
Cantatore FP; Carrozzo M; Magli DM; D'Amore M; Pipitone V
Clin Rheumatol; 1987 Dec; 6(4):504-9. PubMed ID: 3502402
[TBL] [Abstract][Full Text] [Related]
15. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
Wang SX; Li H
Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
[TBL] [Abstract][Full Text] [Related]
16. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
Hodsman AB; Fraher LJ
Bone Miner; 1990 May; 9(2):137-52. PubMed ID: 2161692
[TBL] [Abstract][Full Text] [Related]
17. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
[TBL] [Abstract][Full Text] [Related]
18. Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis.
Pietschmann P; Resch H; Krexner E; Woloszczuk W; Willvonseder R
Acta Med Austriaca; 1991; 18(5):114-6. PubMed ID: 1796722
[TBL] [Abstract][Full Text] [Related]
19. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
Overgaard K
Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
[TBL] [Abstract][Full Text] [Related]
20. Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: a double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover.
van der Wiel HE; Lips P; Nauta J; Kwakkel G; Hazenberg G; Netelenbos JC; van der Vijgh WJ
J Bone Miner Res; 1993 Dec; 8(12):1459-65. PubMed ID: 8304047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
